Hims & Hers Health, Inc. $HIMS Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,146,977 shares of the company’s stock after selling 54,789 shares during the period. Dimensional Fund Advisors LP owned 0.94% of Hims & Hers Health worth $121,800,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Pathway Capital Management LP bought a new position in Hims & Hers Health during the 3rd quarter worth $6,766,000. Steadview Capital Management LLC lifted its stake in Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after buying an additional 311,845 shares during the last quarter. State of Michigan Retirement System boosted its holdings in shares of Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the period. Carnegie Investment Counsel boosted its holdings in shares of Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock valued at $17,238,000 after acquiring an additional 61,560 shares during the period. Finally, BIT Capital GmbH grew its position in shares of Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after acquiring an additional 938,728 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 80,463 shares of company stock valued at $2,846,696 over the last ninety days. Company insiders own 13.71% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

Hims & Hers Health Trading Up 10.3%

Shares of NYSE:HIMS opened at $25.89 on Thursday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a market capitalization of $5.90 billion, a price-to-earnings ratio of 50.76, a PEG ratio of 4.55 and a beta of 2.55. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a 50 day moving average price of $24.18 and a 200 day moving average price of $37.66.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up 28.4% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has authorized a stock repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HIMS shares. Morgan Stanley dropped their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday. TD Cowen cut their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a report on Tuesday, February 24th. Finally, Barclays boosted their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $30.75.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.